Dr Matt Coelho | Postdoctoral Fellow

Coelho, Matthew

Matt is a postdoctoral researcher in the Garnett laboratory focussing on functional genomics strategies to understand molecular pathways involved in sensitivity to cancer immunotherapies. Matt has gained prior expertise in cancer immunotherapy in the laboratory of Julian Downward at the Francis Crick Institute, and CRISPR and Base Editing technologies at AstraZeneca. 


  • Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.

    Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C et al.

    Immunity 2017;47;6;1083-1099.e6

  • BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B.

    Coelho MA, Li S, Pane LS, Firth M, Ciotta G et al.

    BMC biology 2018;16;1;150

  • Involvement of a eukaryotic-like ubiquitin-related modifier in the proteasome pathway of the archaeon Sulfolobus acidocaldarius.

    Anjum RS, Bray SM, Blackwood JK, Kilkenny ML, Coelho MA et al.

    Nature communications 2015;6;8163

Coelho, Matthew